Cubist Pharmaceuticals disclosed this week in a regulatory filing with the Securities and Exchange Commission that it is under investigation by the SEC and Department of Justice for potential violations of the Foreign Corrupt Practices Act.
In a Form 8-K, dated Aug. 11, Cubist said the FCPA allegations concern “a potentially improper payment to a research laboratory” and an “attempted share grant” in 2011 by Optimer Pharmaceuticals, a biopharmaceutical company that Cubist acquired last year.
